Niranjan J Sathianathen,Henry Y C Pan,Marc Furrer et al.
Niranjan J Sathianathen et al.
Background: The benefits of a robot-assisted radical cystectomy (RARC) compared to an open approach is still under debate. Initial data on RARC were from trials where urinary diversion was performed by an extracorporeal a...
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility [0.03%]
历史病原体的选择可能造成了当代种族间膀胱癌易感性的差异
Xiang-Yu Meng,Qiao-Li Wang,Ming-Jun Shi et al.
Xiang-Yu Meng et al.
Background: The rationale for ethnic differences in bladder cancer (BCa) susceptibility is an important open question. In this study, we raised the hypothesis that the APOBEC3-rs1014971 variant associated with BCa risk an...
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study [0.03%]
吉西他滨辅助化疗对根治性肾输尿管切除术后上尿路尿路上皮癌患者的治疗效果：来自倾向性匹配队列研究的结果分析
Zhao Hongda,Liu Kang,Chi-Fai Ng et al.
Zhao Hongda et al.
Background: The evidence regarding perioperative adjuvant chemotherapy and personalized surveillance strategies for upper tract urothelial carcinoma is limited. ...
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough? [0.03%]
免疫检查点抑制剂治疗转移性膀胱癌和其他实体瘤的疗程需多长？
Vivek Kumar,Xiao X Wei
Vivek Kumar
The introduction of T-cell targeted immunomodulators blocking the PD-1 and PD-L1 axis is unquestionably one of the most notable advancements in the treatment of advanced or metastatic solid malignancies, including bladder cancer. Immune che...
Elaine Chang,Noah M Hahn,Seth P Lerner et al.
Elaine Chang et al.
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus...
Mark S Soloway
Mark S Soloway
Edward M Messing
Edward M Messing
The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis [0.03%]
剂量减少的卡介菌对非肌层浸润性膀胱癌患者肿瘤学结果和毒副反应的影响：系统评价和 meta 分析
Wadi Azuri,Jorge Horacio Jaunarena,Juan Jorge Camean et al.
Wadi Azuri et al.
Background: Bacillus Calmette-Guerin (BCG) is the standard adjuvant treatment for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of the bladder (TURB). However, the...
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer [0.03%]
卡介苗无应答高危非肌层浸润性膀胱癌的新型膀胱内药物
Anastasios D Asimakopoulos,Maxim Kochergin,Gaia Colalillo et al.
Anastasios D Asimakopoulos et al.
Background: With the exception of the FDA-approved valrubicin and pembrolizumab, there are no standard second-line treaments for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). ...
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors [0.03%]
膀胱癌幸存者戒烟模式和对电子烟危害感知的关系
Jobin Chandi,Srinath Soundararajan,William Bukowski et al.
Jobin Chandi et al.
Background: Cigarette smoking is the leading preventable cause of bladder cancer (BC). Some proponents of e-cigarettes describe their use as a risk mitigation strategy despite potential carcinogen exposure and uncertain l...